Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Research & Development: 2021-2024

Historic Research & Development for Immunocore Holdings (IMCR) over the last 4 years, with Dec 2024 value amounting to $222.2 million.

  • Immunocore Holdings' Research & Development rose 33.74% to $70.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $256.9 million, marking a year-over-year increase of 24.19%. This contributed to the annual value of $222.2 million for FY2024, which is 35.83% up from last year.
  • Latest data reveals that Immunocore Holdings reported Research & Development of $222.2 million as of FY2024, which was up 35.83% from $163.5 million recorded in FY2023.
  • Immunocore Holdings' Research & Development's 5-year high stood at $222.2 million during FY2024, with a 5-year trough of $100.2 million in FY2021.
  • Over the past 3 years, Immunocore Holdings' median Research & Development value was $163.5 million (recorded in 2023), while the average stood at $162.5 million.
  • Data for Immunocore Holdings' Research & Development shows a peak YoY skyrocketed of 60.46% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows Immunocore Holdings' Research & Development stood at $100.2 million in 2021, then increased by 1.67% to $101.9 million in 2022, then soared by 60.46% to $163.5 million in 2023, then skyrocketed by 35.83% to $222.2 million in 2024.